PROOF 301: A multicenter, open-label, randomized, phase 3 trial of infigratinib versus gemcitabine plus cisplatin in patients with advanced cholangiocarcinoma with an FGFR2 gene fusion/rearrangement Meeting Abstract
| Authors: | Abou-Alfa, G. K.; Borbath, I.; Goyal, L.; Lamarca, A.; Macarulla, T.; Oh, D. Y.; Roychowdhury, S.; Sadeghi, S.; Shroff, R. T.; Li, A.; Soto, J.; Avogadri, F.; Dambkowski, C. L.; Javle, M. M. |
| Abstract Title: | PROOF 301: A multicenter, open-label, randomized, phase 3 trial of infigratinib versus gemcitabine plus cisplatin in patients with advanced cholangiocarcinoma with an FGFR2 gene fusion/rearrangement |
| Meeting Title: | 2022 ASCO Annual Meeting |
| Journal Title: | Journal of Clinical Oncology |
| Volume: | 40 |
| Issue: | 16 Suppl. |
| Meeting Dates: | 2022 Jun 3-7 |
| Meeting Location: | Chicago, IL |
| ISSN: | 0732-183X |
| Publisher: | American Society of Clinical Oncology |
| Date Published: | 2022-06-01 |
| Language: | English |
| ACCESSION: | WOS:000863680304925 |
| PROVIDER: | wos |
| DOI: | 10.1200/JCO.2022.40.16_suppl.TPS4171 |
| Notes: | Meeting Abstract: TPS4171 -- This meeting was also held virtually -- Source: Wos |
